---
layout: default
title: Methoxy Polyethylene Glycol-Epoetin Beta
parent: Low Evidence (L5)
nav_order: 652
evidence_level: L5
indication_count: 10
---

# Methoxy Polyethylene Glycol-Epoetin Beta
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Methoxy polyethylene glycol-epoetin beta: From Anemia of Chronic Kidney Disease to Primary Release Disorder of Platelets

## One-Sentence Summary

Methoxy polyethylene glycol-epoetin beta (Mircera) is a long-acting erythropoiesis-stimulating agent (ESA). The registration record supplied lists no approved indication, but the product is generally used for anemia of chronic kidney disease.
The TxGNN model predicts it may be effective for **primary release disorder of platelets**, with a high score but **no clinical trials and no publications** supporting this direction.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not stated in the supplied HSA record (generally anemia of chronic kidney disease) |
| Predicted New Indication | Primary release disorder of platelets |
| TxGNN Prediction Score | 99.36% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 3 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, this drug is a pegylated form of epoetin beta, an ESA. Its efficacy in anemia has been established, but its mechanism has not been linked to platelet function disorders in the supplied data.

The only plausible link is indirect. ESAs raise hematocrit, and this may improve platelet function in uremic bleeding. That has not been shown for inherited platelet release defects. The prediction is therefore best read as a network-proximity signal in the knowledge graph, not as a mechanistically supported finding.

The other nine top-ranked predictions (scores 98.4% to 99.3%) also have no trials or literature. Most of them fall into two groups:
- **Prothrombotic or bleeding-related conditions**, including Glanzmann thrombasthenia, pseudo-von Willebrand disease, heparin cofactor 2 deficiency, antithrombin deficiency type 2, factor 5 excess with spontaneous thrombosis and thrombophilia. For the thrombophilic conditions, ESAs carry a known thromboembolic risk, so these look more like safety signals than opportunities.
- **Retinal and oncology conditions**, namely diabetic retinopathy (including severe nonproliferative) and HER2 positive breast carcinoma. Erythropoietin signaling is pro-angiogenic in the retina, and ESAs carry a class warning about tumor progression in some cancer settings.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

Currently no related literature available.

## Singapore Market Information

| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---------|------|------|-----------|
| SIN13530P | Mircera Solution for Injection 75mcg/0.3ml (Pre-filled Syringe) | Injection, solution | Not listed in the available record |
| SIN13535P | Mircera Solution for Injection 50mcg/0.3ml (Pre-filled Syringe) | Injection, solution | Not listed in the available record |
| SIN13529P | Mircera Solution for Injection 100mcg/0.3ml (Pre-filled Syringe) | Injection, solution | Not listed in the available record |

All three products are manufactured by F. Hoffmann-La Roche AG and are injectable only.

## Safety Considerations

No package insert warnings, contraindications or drug interaction records were available. Please refer to the package insert for safety information.

Class-level concerns raised in the prediction analysis (not taken from the product label):
- **Thromboembolic risk**: ESAs are associated with venous and arterial thrombotic events. This conflicts with the predicted thrombophilia-type indications.
- **Tumor progression**: ESAs carry a class warning in some cancer settings.
- **Retinal neovascularization**: erythropoietin signaling is pro-angiogenic, which is a concern for diabetic retinopathy.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction rests on the model score alone (Evidence Level L5). There are no trials or publications, and no direct mechanism links an ESA to platelet release disorders. Several other top predictions overlap with known ESA safety risks.

**To proceed, the following is needed:**
- HSA package insert warnings, contraindications and approved indication text (currently a blocking gap for safety screening)
- Mechanism of action data from DrugBank
- A literature and trial search for ESA use in platelet function disorders, especially uremic platelet dysfunction
- A thrombotic risk assessment for any bleeding or coagulation-related indication
- Route compatibility assessment (currently pending)

*This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any application.*
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

